| Literature DB >> 35262506 |
Ulrike Wittig1, Gloria Hohenberger2, Martin Ornig1, Reinhard Schuh3, Andreas Leithner1, Patrick Holweg1.
Abstract
The aim of this study was to determine whether all-arthroscopic repair would lead to improved clinical outcomes, lower complication rates, shorter postoperative immobilization and earlier return to activity compared to open Broström repair in the surgical treatment of chronic lateral ankle instability (CLAI). A systematic literature search was conducted using Pubmed and Embase to identify studies dealing with a comparison of outcomes between all-arthroscopic and open Broström repair for CLAI. The search algorithm was 'ankle instability' AND 'Brostrom' AND 'arthroscopic' AND 'open'. The study had to be written in English language, include a direct comparison of all-arthroscopic and open Broström repair to treat CLAI and have full text available. Exclusion criteria were former systematic reviews, biomechanical studies and case reports. Overall, eight studies met the inclusion criteria and were included in the analysis. Clinical outcomes did not differ substantially between patients treated with either arthroscopic or open Broström repair. Studies that reported on return to activity and sports following surgery suggested that patients that had all-arthroscopic Broström repair returned at a quicker rate. Overall complication rate tended to be lower after arthroscopic Broström repair. Similar to open repair, all-arthroscopic ligament repair for CLAI is a safe treatment option that yields excellent clinical outcomes. Level of Evidence: Level III evidence (systematic review of level I, II and III studies).Entities:
Keywords: Broström; ankle arthroscopy; chronic lateral ankle instability
Year: 2022 PMID: 35262506 PMCID: PMC8788150 DOI: 10.1530/EOR-21-0075
Source DB: PubMed Journal: EFORT Open Rev ISSN: 2058-5241
Overview of included studies.
| Reference | Study design | Level of evidence | Minors, n | Patients, n | Age (years)* | Gender ratio (M/F) | Follow-up (months)* |
|---|---|---|---|---|---|---|---|
| Zhou | RCS | III | 18 | ||||
| AI | 31 | 33.4 ± 6.4 | 20/11 | 29.7 ± 3.4 | |||
| O | 36 | 31.4 ± 7.8 | 23/13 | 33.1 ± 6.8 | |||
| Woo | RCS | III | 19 | ||||
| AI | 26 | 33.4 ± 10.6 | 16/10 | 12 | |||
| O | 26 | 31.5 ± 10.3 | 16/10 | 12 | |||
| Zeng | RCS | III | 18 | NA | |||
| AI | 17 | 30.9 ± 6.0 | 15/2 | ||||
| O | 10 | 27.7 ± 9.7 | 7/3 | ||||
| Xu | RCS | III | 22 | ||||
| AI | 32 | 33.7 ± 7.0 | 24/8 | 36.5 ± 12.7 | |||
| O | 35 | 35.8 ± 8.5 | 25/10 | 39.1 ± 9.2 | |||
| Rigby | RCS | III | 18 | ||||
| AI | 30 | 47.9 (14–83) | 9/21 | 15.6 (8.4–20.4) | |||
| O | 32 | 37.7 (9–72) | 14/18 | 44.4 (15.6–63.6) | |||
| Li | RCS | III | 20 | ||||
| AI | 23 | 30.3 ± 10.1 | 18/5 | 39.7 ± 10.3 | |||
| O | 37 | 28.7 ± 8.7 | 29/8 | 35.5 ± 9.9 | |||
| Yeo | RCT | I | |||||
| AI | 25 | 35.2 (19–54) | 7/18 | 12 | |||
| O | 23 | 34.3 (17–52) | 12/11 | 12 | |||
| Matsui | RCS | III | 17 | ||||
| AI | 19 | 28 (8–59) | 12/7 | 12 | |||
| O | 18 | 24 (13–56) | 8/10 | 12 |
*Data are presented as mean ± s.d. or as mean (range).
AA, arthroscopically assisted Broström; AI, all-inside arthroscopic Broström; F, female; M, male; NA, not applicable; O, open Broström; RCS, retrospective cohort study; RCT, randomized controlled trial.
Figure 1PRISMA flow diagram of the identification of relevant studies.
Evaluation of clinical outcomes. Data are presented mean ± s.d., mean (s.e.m.) or as mean (range).
| Reference | AOFAS | VAS | Karlsson score |
|---|---|---|---|
| Zhou | |||
| AI | 91.71 ± 5.46 | 1.74 ± 1.24 | 87.52 ± 7.59 |
| O | 90.67 ± 5.59 | 1.58 ± 1.2 | 88.75 ± 5.56 |
| Woo | |||
| AI | 94.2 ± 10.0 | 1.2 ± 2.7 | |
| O | 70.9 ± 33.1 | 2.1 ± 2.6 | |
| Zeng | |||
| AI | 92.4 ± 5.9 | 89.2 ± 8.4 | |
| O | 91.1 ± 6.2 | 90.5 ± 8.8 | |
| Xu | |||
| AI | 87.7 ± 7.6 | 1.8 ± 1.6 | 83.1 ± 8.2 |
| O | 86.9 ± 7.3 | 2.1 ± 1.7 | 81.7 ± 9.1 |
| Rigby | |||
| AI | 95.33 (55–100) | 1.5 (0–10) | 91.8 (55–100) |
| O | 93.53 (49–100) | 1.2 (0–9.5) | 93.41 (54–100) |
| Li | |||
| AI | 93.3 ± 8.9 | 90.3 ± 12.5 | |
| O | 92.4 ± 8.6 | 89.4 ± 10.6 | |
| Yeo | |||
| AI | 90.3 (2.4) | 1.7 (0.4) | 76.2 (2.8) |
| O | 89.2 (2.3) | 2.0 (0.4) | 73.5 (2.8) |
| Matsui | NA | ||
| AI | 1.24 (0–5.5) | ||
| O | 1.92 (0.4–6.2) |
AI, all-inside arthroscopic Broström; AA, arthroscopically assisted Broström; O, open Broström; TTA, talar tilt angle.
Figure 2Results of aggregate analysis for the comparison of AOFAS scores between AI and O groups. IV, inverse variance.
Figure 3Results of aggregate analysis for the comparison of total VAS scores between AI and O groups. IV, inverse variance.
Figure 4Results of aggregate analysis for the comparison of Karlsson scores between AI and O groups. IV, inverse variance.
Evaluation of postoperative treatment and rehabilitation protocols.
| Reference | Postoperative mobilization | Return to activity* |
|---|---|---|
| Zhou | ||
| AI & O | Short cast for 2 weeks | |
| Ankle brace for 4 weeks | ||
| Partial weightbearing 4 weeks after surgery, followed by progressive weightbearing | ||
| Woo | Full return allowed after 3 months | |
| AI & O | Posterior splint, non-weightbearing for 2 weeks | |
| Full weightbearing after 2 weeks, walking boot for 4 weeks | ||
| Zeng | ||
| AI & O | Short cast for 2 weeks, followed by walking boot | |
| Full weightbearing after 6–12 weeks | ||
| Xu | ||
| AI & O | Ankle brace for 6 weeks | |
| Partial weight bearing after 4 weeks | ||
| Full weightbearing after 6 weeks | ||
| Rigby | ||
| AI | Below knee splint for 10 days non-weightbearing | Mean time (days) to weightbearing: 12 (9–16) |
| Short leg cast 50% weightbearing for 10 days | 97% returned to full activity | |
| Full weightbearing in a walking cast for 7–10 days | ||
| O | Splint for 10–14 days non-weightbearing | Mean time (days) to weightbearing: 22 (20–26) |
| Progressive weightbearing in a cast or boot after 3 weeks | 97% returned to full activity | |
| Li | ||
| AI & O | Short leg cast for 2 weeks | |
| Ankle brace after 2 weeks | ||
| Weightbearing permitted after 4 weeks | ||
| Yeo | ||
| AI & O | Posterior splint for 2 weeks non-weightbearing | Straight running allowed after 8 weeks |
| Short-leg walking cast for 2 weeks with progressive weightbearing | Full return after 12 weeks | |
| Splint for 2 weeks | ||
| Matsui | ||
| AI & O | Splint for several days, immediate weightbearing, followed by ankle brace for 6–8 weeks | |
| AI | Return (weeks) to daily activity: 5.3 (3–12) | |
| Return (weeks) to sports: 16.5 (12–22) | ||
| O | Return (weeks) to daily activity: 7.1 (5–12); ( | |
| Return (weeks) to sports: 17.1 (13–22); ( |
*Data presented as mean (range).
Complication rates.
| Reference | Complication rate, % | Impaired wound healing, % | Irritation of peroneal nerve, % | Knot pain, % | Revision surgery, % |
|---|---|---|---|---|---|
| Zhou | |||||
| AI | 6.5 (2/31) | 0.0 (0/31) | 3.2 (1/31) | 0.0 (0/31) | 0.0 (0/31) |
| O | 11.1 (4/36) | 0.0 (0/36) | 2.8 (1/36) | 2.8 (1/36) | 0.0 (0/36) |
| Woo | |||||
| AI | 0.0 (0/26) | 0.0 (0/26) | 0.0 (0/26 | 0.0 (0/26) | 0.0 (0/26) |
| O | 0.0 (0/26) | 0.0 (0/26) | 0.0 (0/26) | 0.0 (0/26) | 0.0 (0/26) |
| Zeng | |||||
| AI | 11.8 (2/17) | 5.9 (1/17) | 5.9 (1/17) | 0.0 (0/17) | 0.0 (0/17) |
| O | 30.0 (3/10) | 20 (2/10) | 0.0 (0/10) | 10.0 (1/10) | 0.0 (0/10) |
| Xu | |||||
| AI | 15.6 (5/32) | 0.0 (0/32) | 9.4 (3/32) | 6.3 (2/32) | 0.0 (0/32) |
| O | 14.3 (5/35) | 5.7 (2/35) | 5.7 (2/35) | 0.0 (0/35) | 0.0 (0/35) |
| Rigby | |||||
| AI | 6.7 (2/30) | 0.0 (0/30) | 3.3 (1/30) | 0.0 (0/30) | 0.0 (0/30) |
| O | 6.3 (2/32) | 0.0 (0/32) | 6.3 (2/32) | 0.0 (0/32) | 0.0 (0/32) |
| Li | |||||
| AI | 4.3 (1/23) | 0.0 (0/23) | 0.0 (0/23) | 0.0 (0/23) | 0.0 (0/23) |
| O | 5.4 (2/37) | 0.0 (0/37) | 0.0 (0/37) | 0.0 (0/37) | 0.0 (0/37) |
| Yeo | |||||
| AI | 20.0 (5/25) | 0.0 (0/25) | 12.0 (3/25) | 8.0 (2/25) | 4.0 (1/25) |
| O | 13.0 (3/23) | 4.3 (1/23) | 8.7 (2/23) | 0.0 (0/23) | 0.0 (0/23) |
| Matsui | |||||
| AI | 10.5 (2/19 | 0.0 (0/19) | 10.5 (2/19) | 0.0 (0/19) | 0.0 (0/19) |
| O | 22.2 (4/18) | 16.7 (3/18) | 5.6 (1/18) | 0.0 (0/18) | 0.0 (0/18) |
Figure 5Results of aggregate analysis for the comparison of overall complication rates between BR and ST groups. Numbers for ‘events’ refer to failure; numbers for ‘total’ refer to total participants. M–H, Mantel–Haenszel method.
Figure 6Results of aggregate analysis for the comparison of rates for irritation of woundhealing between BR and ST groups. Numbers for ‘events’ refer to failure; numbers for ‘total’ refer to total participants. M–H, Mantel–Haenszel method.
Figure 7Results of aggregate analysis for the comparison of rates for irritation of peroneal nerve and tendons between BR and ST groups. Numbers for ‘events’ refer to failure; numbers for ‘total’ refer to total participants. M–H, Mantel–Haenszel method.
Figure 8Results of aggregate analysis for the comparison of knot pain rates between BR and ST groups. Numbers for ‘events’ refer to failure; numbers for ‘total’ refer to total participants. M–H, Mantel–Haenszel method.